Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical

MGI/SuperGen Estimate Dacogen Peak Sales Of $250 Mil.; Action Date Is Sept. 1

This article was originally published in Pharmaceutical Approvals Monthly

  • News
  • Pharmaceutical Approvals Monthly

Executive Summary

MGI and SuperGen estimate their myelodysplastic syndrome agent Dacogen has a market potential of $250 mil., SuperGen said July 21.

You may also be interested in...



MGI Submits Saforis NDA: Pipeline To Propel Sales To $1 Bil. By 2010 – Firm

MGI Pharma’s recently submitted oral mucositis therapy Saforis and newly approved myelodysplastic syndromes agent Dacogen top a "deep and maturing pipeline" projected to drive corporate sales to $1 bil. by 2010, according the company.

MGI/SuperGen’s Dacogen Is "Approvable" Pending Transfusion Data Analysis

MGI/SuperGen’s myelodysplastic syndromes therapy Dacogen (decitabine) is "approvable" at FDA pending submission of additional analysis of transfusion data

MGI Purchase Of Guilford Will Create Two-Product Acute Care Sales Force

MGI Pharma's acquisition of Guilford will forge a two-product acute care sales force

Table

View full table

Topics

Tags:
BioPharmaceutical
UsernamePublicRestriction

Register

LL035386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By